CA2600144A1 — Compounds and compositions as protein kinase inhibitors
Assigned to IRM LLC · Expires 2006-09-28 · 20y expired
What this patent protects
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that …
USPTO Abstract
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, BMX, BTK, CHK2, c-RAF, CSK, c-SRC, Fes, FGFR3, Flt3, IKK.alpha. , IKK.beta., JNK2.alpha. 2, Lck, Met, MKK4, MKK6, MST2, NEK2, p70S6K, PDGFR.beta. , PKA, PKB .beta., PKD2, Rsk1, SAPK2.alpha. , SAPK2.beta. , SAPK3, SGK, Tie2 and TrkB kinases.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.